A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 PhosphoStat-B是一种针对BLyS的全人源IgG 1单克隆抗体。 本研究是一项在系统性红斑狼疮受试者中评价AnaphoStat-B抗体（抗BLyS单克隆抗体）的安全性、耐受性和有效性的II期、多中心、双盲、安慰剂对照剂量范围研究，旨在评价AnaphoStat-B的安全性、耐受性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. LymphoStat-B is a fully human IgG1 monoclonal antibody to BLyS. The study, a phase II multi-center, double-blind, placebo-controlled dose-ranging study to evaluate the safety, tolerability and efficacy of LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus, is designed to evaluate the safety and tolerability and efficacy of LymphoStat-B.